MTAP loss found in 17% of NSCLC by IHC, more often in driver-positive stage IV disease
Stephen V Liu summarised a study characterising MTAP loss by immunohistochemistry in non-small cell lung cancer, including lung–lymph node concordance and in vitro PRMT5 inhibition.
“In stage IV, more in driver pos (24%) than driver neg (14%).”— Stephen V Liu, MD
Thoracic oncologist Stephen V Liu summarised findings on MTAP loss in non-small cell lung cancer (NSCLC) in a post on X, tagging the journal account @CCR_AACR.
According to Liu's summary, the study characterised MTAP loss using immunohistochemistry (IHC). MTAP loss was seen in 17%. Among stage IV cases, loss was more frequent in driver-positive disease (24%) than in driver-negative disease (14%).
Liu also reported 64% concordance in MTAP status between lung and lymph node samples.
In vitro experiments showed variable sensitivity to PRMT5 inhibition, Liu wrote, adding "more combined with TKI". The post links to the full paper, and details beyond this summary were not given in the post.
Original source
“In stage IV, more in driver pos (24%) than driver neg (14%).”
— Stephen V Liu, MD View the post on X
